Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
Division of Cardiology, University of Texas Health Science Center, Houston, 77030, USA. david.aguilar@uth.tmc.edu
David
D
Aguilar
Samuel Z
SZ
Goldhaber
Daniel J
DJ
Gans
Andrew S
AS
Levey
Jerome G
JG
Porush
Julia B
JB
Lewis
Jean-Lucien
JL
Rouleau
Tomas
T
Berl
Edmund J
EJ
Lewis
Marc A
MA
Pfeffer
D000328:Adult; D000368:Aged; D001713:Biphenyl Compounds / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D003925:Diabetic Angiopathies / Q000175:diagnosis* / Q000401:mortality; D003928:Diabetic Nephropathies / Q000175:diagnosis* / Q000401:mortality; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis* / Q000401:mortality; D015994:Incidence; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D013777:Tetrazoles / Q000008:administration & dosage; D016896:Treatment Outcome
D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan